SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label#single center #non-randomized #Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients with advanced stage hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: SHR-1210|DRUG: apatinib
Objective response rate(ORR), Evaluated by researchers based on the RECIST 1.1 standard, 2 years
Progression free survival(PFS), Evaluated by researchers based on the RECIST 1.1 standard, 2 years|To the relief time (TOR), Evaluated by researchers based on the RECIST 1.1 standard, 2 years|Duration of relief(DOR), Evaluated by researchers based on the RECIST 1.1 standard, 2 years|Disease Control Rate (DCR), Evaluated by researchers based on the RECIST 1.1 standard, 2 years|9-month survival rate, 9-month|12-month survival rate, 12-month|Overall survival (OS), 10 years
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label#single center #non-randomized #Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 and apatinib in patients with advanced stage hepatocellular carcinoma.